Top
image credit: Unsplash

Merck KGaA to buy gene therapy tools maker for $600M

May 23, 2024

Merck KGaA’s dual roles as a CDMO and traditional pharmaceutical research company make it increasingly rare in the industry. The company also has an electronics unit with expertise in semiconductors, displays and surface materials.

The purchase of Mirus helps to shore up the company’s offerings in an area of contract manufacturing that has far more demand than supply. There have been more than 20 approvals for viral vector-based cell and gene therapies in the last 10 years, with a projected growth of 30% to 2028, according to statistics cited by Merck KGaA.

Read More on Biopharma Dive